Form 4: Protagenic Therapeutics Director Acquires Options

Robert Benjamin Stein, a director of Protagenic Therapeutics, acquired options for 75,000 shares of PTIX common stock on March 25, 2024.

Summary

• Robert Benjamin Stein, a director of Protagenic Therapeutics, filed a Form 4 indicating a change in beneficial ownership.
• On March 25, 2024, Stein acquired options to purchase 75,000 shares of PTIX common stock at an exercise price of $1.74.
• 50,000 of the options are fully exercisable starting March 25, 2026.
• The remaining 25,000 options become exercisable upon the company consummating a corporate partnership before December 31, 2026; otherwise, they will never be exercisable.
• The options expire on March 25, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring options suggests confidence, but the contingent nature of some options introduces uncertainty.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Risks

• 25,000 of the options are contingent on a corporate partnership being formed before the end of 2026, which may not occur.

Future Outlook

The exercisability of 25,000 options is contingent on the company entering into a corporate partnership before December 31, 2026, which introduces uncertainty.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's increased stake in the company through options.

Stakeholder Impact

• The acquisition of options by a director could positively influence shareholder sentiment.

Key Dates

Keywords

Form 4, beneficial ownership, Protagenic Therapeutics, PTIX, options, Robert Benjamin Stein, director